A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
Active, not recruiting · Phase 1, Phase 2 · NCT03157128
Conditions: Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
At a glance
- Research payments reported, 2025
- $2.6M
- U.S. investigators named
- 28
- Sites paid
- 25
- Planned or actual enrollment
- 857
About the trial
- Sponsor
- Eli Lilly and Company (with Loxo Oncology, Inc.)
- Tested
- LOXO-292 (drug)
- Dates
- Started 2017-05-02; completion 2027-02
- Results posted
- Yes
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.
From ClinicalTrials.gov, last updated 2026-04-16. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $2.6M in research payments for this study in 2025 (28 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Nina J. Karlin, M.D. Hematology & Oncology · Scottsdale, AZ
- Lyudmila A. Bazhenova, M.D. Hematology & Oncology · San Diego, CA
- Jonathan W. Goldman, M.D. Hematology & Oncology · Santa Monica, CA
- Hyunseok Kang, MD Medical Oncology · Stanford, CA
- Mingqing Li, M.D. Student in an Organized Health Care Education/Training Program · Carmichael, CA
- Misako Nagasaka, MD Hematology & Oncology · Orange, CA
- Gerald S. Falchook, MD Medical Oncology · Denver, CO
- Frederick H. Wilson Medical Oncology · New Haven, CT
- Conor E. Steuer, MD Hematology & Oncology · Atlanta, GA
- Mark E. Burkard, M.D. Medical Oncology · Iowa City, IA
- Christine M. Bestvina, M.D. Medical Oncology · Chicago, IL
- Marc R. Matrana, M.D. Hematology & Oncology · New Orleans, LA
- Jacob M. Sands, MD Hematology & Oncology · Burlington, MA
- Lori J. Wirth, MD Medical Oncology · Boston, MA
- Benjamin P. Levy, MD Hematology & Oncology · Baltimore, MD
- Nehal J. Lakhani, M.D. Hematology & Oncology · Grand Rapids, MI
- Francis P. Worden, MD Medical Oncology · Ann Arbor, MI
- John C. Morris III, M.D. Endocrinology & Diabetes · Rochester, MN
- Jared M. Weiss, M.D. Hematology & Oncology · Chapel Hill, NC
- Alexander Edward D. Drilon, MD Medical Oncology · New York, NY
- Grace K. Dy, MD Hematology & Oncology · Buffalo, NY
- Nathan A. Pennell, MD PHD Hematology & Oncology · Cleveland, OH
- Vineeth K. Sukrithan, MD Medical Oncology · Columbus, OH
- Shivaani Kummar Medical Oncology · Portland, OR
- Marcia S. Brose, MD Medical Oncology · Philadelphia, PA
- David R. Spigel, M.D. Medical Oncology · Nashville, TN
- Tian Zhang, M.D. Medical Oncology · Dallas, TX
- Wallace L. Akerley III, MD Medical Oncology · Salt Lake City, UT
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Dana Farber PArtners Cancer Care Inc $830,304
- University of North Carolina at Chapel Hill $828,292
- Memorial Sloan-Kettering $183,129
- University of Chicago $165,645
- The Ohio State University $96,808
- Mayo Clinic $94,787
- University of Utah Hospital and Clinics, UT $88,968
- Thomas Jefferson University $53,452
- Ronald Reagan UCLA Medical Center, CA $44,797
- Johns Hopkins University $39,133
- The University of Texas $33,746
- University of Michigan Health System, MI $32,697
- University of California, San Francisco (ucsf) - Helen Diller Family Comprehensive Cancer Center (US $28,985
- Cleveland Clinic, OH $22,046
- Ohsu Hospital and Clinics, OR $20,658
- Sarah Cannon Research Institute LLC $18,648
- Regents of the University of California $16,280
- Board of Regents of the Univ of Wisconsin Systm $14,888
- Start Ctr for Cancer Care $14,850
- Emory University Hospital, GA $7,332
- Kaiser Foundation Hospital-Santa Clara, CA $5,056
- Uci Health-Orange, CA $3,948
- Health Research Inc $2,840
- Ochsner Medical Center Acute, LA $2,138
- Yale University $250
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.